Germany · Delayed Price · Currency is EUR Xenon Pharmaceuticals Statistics
Total Valuation
FRA:XP0 has a market cap or net worth of EUR 2.98 billion. The enterprise value is 2.51 billion.
| Market Cap | 2.98B |
| Enterprise Value | 2.51B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 77.28M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.00% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 103.29% |
| Float | 71.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 466.23 |
| PB Ratio | 6.25 |
| P/TBV Ratio | 6.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.61 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.62 |
Financial Position
The company has a current ratio of 12.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.52 |
| Quick Ratio | 12.08 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.14% and return on invested capital (ROIC) is -30.97%.
| Return on Equity (ROE) | -45.14% |
| Return on Assets (ROA) | -29.51% |
| Return on Invested Capital (ROIC) | -30.97% |
| Return on Capital Employed (ROCE) | -59.84% |
| Revenue Per Employee | 19,852 |
| Profits Per Employee | -810,834 |
| Employee Count | 327 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.87M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.45% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -5.45% |
| 50-Day Moving Average | 34.46 |
| 200-Day Moving Average | 31.08 |
| Relative Strength Index (RSI) | 68.13 |
| Average Volume (20 Days) | 27 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.79 |
Income Statement
In the last 12 months, FRA:XP0 had revenue of EUR 6.39 million and -261.09 million in losses. Loss per share was -3.31.
| Revenue | 6.39M |
| Gross Profit | -226.04M |
| Operating Income | -290.45M |
| Pretax Income | -263.96M |
| Net Income | -261.09M |
| EBITDA | -288.23M |
| EBIT | -290.45M |
| Loss Per Share | -3.31 |
Balance Sheet
The company has 393.99 million in cash and 7.10 million in debt, giving a net cash position of 466.15 million.
| Cash & Cash Equivalents | 393.99M |
| Total Debt | 7.10M |
| Net Cash | 466.15M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 476.87M |
| Book Value Per Share | 6.18 |
| Working Capital | 376.55M |
Cash Flow
In the last 12 months, operating cash flow was -214.80 million and capital expenditures -1.08 million, giving a free cash flow of -215.88 million.
| Operating Cash Flow | -214.80M |
| Capital Expenditures | -1.08M |
| Free Cash Flow | -215.88M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,543.73% |
| Pretax Margin | -4,129.39% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:XP0 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.00% |
| Shareholder Yield | -4.00% |
| Earnings Yield | -8.76% |
| FCF Yield | -7.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:XP0 has an Altman Z-Score of 31.35 and a Piotroski F-Score of 1.
| Altman Z-Score | 31.35 |
| Piotroski F-Score | 1 |